Anti-streptokinase Antibody Detection before and Immediately after Streptokinase Therapy in Patients with Myocardial Infarction

Authors

  • Abbas Rezaei Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  • Hasan Shemirani Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract:

Background: Myocardial infarction (MI) is one of the most common and serious diseases resulting from coronary artery occlusion and major reduction in blood flow. Streptokinase as a thrombolytic is considered the first and most important therapeutic intervention for reperfusion following MI in most countries including Iran. Our previous study showed that, the prevalence of high antibody titers against streptokinase was 13.5% in the studied population from Iran, which was 2.5 times more common than data from other studies. Objective: To evaluate anti-streptokinase antibody titers before and immediately after streptokinase administration and its relation to reperfusion therapy success rates. Methods: A total of 200 patients with acute MI was selected. Antibodies against streptokinase were measured before and 2 days after administration of streptokinase. Before streptokinase administration and every hour after streptokinase administration, for 3 consecutive hours, an ECG was taken from each participant and changes were evaluated in relation to antibody levels. Results: Out of 200 patients, 42 (21%) had high levels of antibody titer. Out of these 42 patients, 13 (6.5%) still had measurable levels of anti-streptokinase antibody after streptokinase administration. Conclusion: Our results show the ability of the antistreptokinase antibody to neutralize the effects of streptokinase.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

anti-streptokinase antibody detection before and immediately after streptokinase therapy in patients with myocardial infarction

background: myocardial infarction (mi) is one of the most common and serious diseases resulting from coronary artery occlusion and major reduction in blood flow. streptokinase as a thrombolytic is considered the first and most important therapeutic intervention for reperfusion following mi in most countries including iran. our previous study showed that, the prevalence of high antibody titers a...

full text

Can anti-streptokinase antibody predict myocardial infarction outcomes after streptokinase treatment?

BACKGROUND The aim of this study was finding the association between anti- Streptokinase (SK) levels based on previous streptococcus infection and the clinical outcome of acute myocardial infarction (AMI) among Iranian patients after SK treatment. METHODS In this prospective study, 31 consecutive patients presented to the emergency room of a referral university hospital within six hours of th...

full text

Assessment of Anti-streptokinase Antibody in Patients with Heart Diseases and Normal Subjects

Background: Streptokinase, which is injected intravenously with a standard dose of 1.5 MIU, is the most widely used thrombolytic agent around the world. What is so important about this bioproduct is the level of antistreptokinase (anti-sk) antibody in the population, which is directly correlated to the incidence of streptococcal infections in that population. Objective: Since Iran is an endemic...

full text

The streptokinase therapy complications and its associated risk factors in patients with acute ST elevation myocardial infarction

Acute myocardial infarction (AMI) is one of the main leading causes of mortality and morbidity. Despite the progress in the treatment of AMI, streptokinase is still being used in many countries. Because of the critical condition of patients with AMI and complications of streptokinase therapy, this study was performed to evaluate the pattern of adverse drug reaction (ADRs) induced by streptokina...

full text

Guillain-Barré syndrome after streptokinase therapy for acute myocardial infarction.

Some drugs including streptokinase have been reported to precipitate Guillain-Barré syndrome. We report a 70-year-old man with acute anterior myocardial infarction who developed Guillain-Barré syndrome seven days after thrombolytic therapy with streptokinase.

full text

Transmural , haemorrhagic myocardial infarction after intracoronary streptokinase

Six of 101 patients with acute myocardial infarction whose coronary arteries were successfully recanalised died in cardiogenic shock one to 18 days after intracoronary thrombolysis. In one patient, cardiogenic shock was preceded by coronary artery reocclusion. On admission, serum creatine kinase was still normal in all six patients and there was significant ST elevation but no changes in the QR...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 3  issue 2

pages  66- 69

publication date 2006-06-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023